AD17002 Treating Poorly Controlled, Moderate to Severe Eosinophilic Asthma
Status:
Recruiting
Trial end date:
2024-09-27
Target enrollment:
Participant gender:
Summary
This clinical trial aims to investigate patients with poorly controlled, moderate to severe
eosinophilic asthma. The main questions it aims to answer are
1. Could the LTh(αK) intranasal treatment improve the clinical condition of these patients?
2. Could patients self-administrate LTh(αK) via the intranasal route?
3. Is the LTh(αK) at multiple doses safe for asthmatic patients?
4. Participants will be asked to self-administrate two doses per week for a total of 6
weeks (11 doses). A diary on LTh(αK) usage, adverse events, and reliever medication will
be recorded.